Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773 Pseudomonas aeruginosa high-risk clone.

Corticosteroids modulate biofilm formation and virulence of Pseudomonas aeruginosa.

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.

Spanish nationwide survey of Pseudomonas aeruginosa cefiderocol susceptibility and resistance mechanisms.

Study of the probability of resistance to phage infection in a collection of clinical isolates of Pseudomonas aeruginosa in relation to the presence of Pf phages.

An antisense peptide-conjugated peptide nucleic acid (PPNA) for peptidoglycan recycling inhibition reduces AmpC hyperproduction and β-lactam resistance in Pseudomonas aeruginosa.

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain: Findings from the Multicenter ITUBRAS-2 Cohort Study.

How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today’s clinicians.

Pseudomonas aeruginosa chronic infections in patients with bronchiectasis: a silent reservoir of carbapenemase-producing epidemic high-risk clones.

Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.